Abstract
Introduction: papillary thyroid microcarcinoma is a well-known malignant neoplasm with good prognosis. The known prognostic factors are patient's age, multifocality, and extrathyroidal extension. CD9 and CD82, members of the tetraspanin family, are expressed in numerous cancer cells and play many roles associated with the cellular process. Material and methods: we investigated the immunohistochemical expression of CD9 and CD82 in papillary thyroid microcarcinoma and analysed the clinicopathological and prognostic significance. For the retrospective analysis, we collected the cases of 553 PTMC patients who had undergone thyroidectomy. Results: The group with lymph node metastasis showed higher immunostaining intensity for CD9 than the group without metastasis (p = 0.002). In multivariate analysis, high CD9 intensity (OR = 1.58 in 3+, p = 0.0025) correlated with lymph node metastasis. Conclusion: We suggest CD9 as a predictive prognostic factor for lymph node metastasis in PTMC.
| Original language | English |
|---|---|
| Pages (from-to) | 224-231 |
| Number of pages | 8 |
| Journal | Endokrynologia Polska |
| Volume | 70 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
}
Expression of CD9 and CD82 in papillary thyroid microcarcinoma and its prognostic significance. / Kim, Taeyeong; Kim, Yonhee; Kwon, Hyeong Ju.
In: Endokrynologia Polska, Vol. 70, No. 3, 01.01.2019, p. 224-231.Research output: Contribution to journal › Article
TY - JOUR
T1 - Expression of CD9 and CD82 in papillary thyroid microcarcinoma and its prognostic significance
AU - Kim, Taeyeong
AU - Kim, Yonhee
AU - Kwon, Hyeong Ju
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: papillary thyroid microcarcinoma is a well-known malignant neoplasm with good prognosis. The known prognostic factors are patient's age, multifocality, and extrathyroidal extension. CD9 and CD82, members of the tetraspanin family, are expressed in numerous cancer cells and play many roles associated with the cellular process. Material and methods: we investigated the immunohistochemical expression of CD9 and CD82 in papillary thyroid microcarcinoma and analysed the clinicopathological and prognostic significance. For the retrospective analysis, we collected the cases of 553 PTMC patients who had undergone thyroidectomy. Results: The group with lymph node metastasis showed higher immunostaining intensity for CD9 than the group without metastasis (p = 0.002). In multivariate analysis, high CD9 intensity (OR = 1.58 in 3+, p = 0.0025) correlated with lymph node metastasis. Conclusion: We suggest CD9 as a predictive prognostic factor for lymph node metastasis in PTMC.
AB - Introduction: papillary thyroid microcarcinoma is a well-known malignant neoplasm with good prognosis. The known prognostic factors are patient's age, multifocality, and extrathyroidal extension. CD9 and CD82, members of the tetraspanin family, are expressed in numerous cancer cells and play many roles associated with the cellular process. Material and methods: we investigated the immunohistochemical expression of CD9 and CD82 in papillary thyroid microcarcinoma and analysed the clinicopathological and prognostic significance. For the retrospective analysis, we collected the cases of 553 PTMC patients who had undergone thyroidectomy. Results: The group with lymph node metastasis showed higher immunostaining intensity for CD9 than the group without metastasis (p = 0.002). In multivariate analysis, high CD9 intensity (OR = 1.58 in 3+, p = 0.0025) correlated with lymph node metastasis. Conclusion: We suggest CD9 as a predictive prognostic factor for lymph node metastasis in PTMC.
UR - http://www.scopus.com/inward/record.url?scp=85068570428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068570428&partnerID=8YFLogxK
U2 - 10.5603/EP.a2019.0009
DO - 10.5603/EP.a2019.0009
M3 - Article
C2 - 30794730
AN - SCOPUS:85068570428
VL - 70
SP - 224
EP - 231
JO - Endokrynologia Polska
JF - Endokrynologia Polska
SN - 0423-104X
IS - 3
ER -